Proteome Sciences (PRM) AI Stock Analysis

• Market Cap: £6.31M
• Dividend Yield: N/A
• Average Volume (3M): 476.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: 12.19%
• EPS Growth: 18.12%
• Country: UK
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 343,182,070
• 10 Day Avg. Volume: 209,671
• 30 Day Avg. Volume: 476,642
• PEG Ratio: -0.08
• Price to Book (P/B): -1.54
• Price to Sales (P/S): 2.05
• P/FCF Ratio: -9.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: 2.00p ▼(-29.82% Downside)

The score is held down primarily by very weak financial performance (declining revenue, ongoing losses, negative cash flow, and negative equity). Technicals are also bearish with the stock below key moving averages, though oversold signals modestly offset the downside. Valuation is unfavorable due to a negative P/E and no dividend support.

Positive Factors

Specialized Proteomics Expertise

Proteome Sciences' core capability in mass spectrometry and biomarker discovery is a durable technical moat. High scientific complexity and specialized instrumentation create barriers to entry, supporting long-term client relationships with pharma/biotech and enabling premium, hard-to-replicate service offerings.

Fee-for-Service Contract Research Model

A fee-for-service contract research model produces recurring project-based revenues and multi-client exposure. Long-term partnerships and repeat studies with pharma, biotech, and academia can provide stable revenue streams and predictable project pipelines, supporting multi-month operational planning.

Exposure to Personalized Medicine Demand

Operating squarely in proteomics and diagnostics ties the business to secular growth in personalized medicine and biomarker-driven drug development. This structural industry tailwind increases the addressable market and the likelihood of sustained demand for specialized analytical services over the medium term.

Negative Factors

Negative Equity / Solvency Risk

Negative stockholders' equity is a material solvency concern that limits financial flexibility. It raises the likelihood of higher funding costs or equity dilution, constrains investment in R&D and capacity expansion, and can impair long-term competitiveness if not remedied through sustained profitability or recapitalization.

Negative Operating and Free Cash Flow

Persistent negative operating and free cash flow indicate structural cash-generation problems. Without positive OCF, the company must rely on external financing for operations and capex, increasing execution risk and potentially limiting the ability to sustain service delivery, invest in equipment, or hire technical staff.

Declining Revenue and Ongoing Losses

A drop in revenue alongside negative EBIT and net margins suggests the business isn't scaling fixed-cost operations effectively. Continued top-line decline and losses erode runway, weaken negotiating power with clients, and reduce resources for R&D and commercialization, posing sustained operational risk.

Proteome Sciences Business Overview & Revenue Model

Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

How the Company Makes Money

Proteome Sciences generates revenue primarily through its contract research services, which involve offering proteomics analysis and biomarker discovery to pharmaceutical and biotechnology companies. These services are often provided on a fee-for-service basis, where clients pay for specific projects or studies tailored to their research needs. Additionally, the company may earn income from collaborations and partnerships with academic institutions and industry players, enabling shared research initiatives and technology licensing. Furthermore, Proteome Sciences could also monetize its proprietary technologies and software tools through licensing agreements, contributing to its overall revenue stream.

Proteome Sciences Financial Statement Overview

Summary

Very weak fundamentals: declining revenue, negative profitability (EBIT and net margins), negative operating/free cash flow, and negative equity indicating liabilities exceed assets—raising solvency risk.

Income Statement

The company has experienced declining revenue with a decrease from 5.03 million to 4.89 million over the last year, indicating a negative revenue growth rate. The negative EBIT and net income margins highlight ongoing operational challenges with profitability. These factors indicate financial instability in the income statement.

Balance Sheet

The company has a negative stockholders' equity, indicating that liabilities exceed assets, which is a significant concern. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt level suggests potential solvency issues. This balance sheet position suggests high financial risk.

Cash Flow

Operating cash flow is negative, and free cash flow has worsened, indicating cash flow difficulties. The free cash flow to net income ratio is negative, reflecting challenges in generating cash relative to net income. These factors demonstrate weak cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.53M	4.89M	5.03M	23.74B	22.59B	16.95B
Gross Profit	-32.00K	670.00K	1.65M	4.77M	2.96M	2.58M
EBITDA	-1.45M	-1.51M	-1.14M	2.13M	625.00K	714.00K
Net Income	-3.33M	-3.41M	-2.44M	1.32M	72.00K	295.00K
Balance Sheet
Total Assets	8.35M	9.21M	11.46M	12.43M	10.04M	9.09M
Cash, Cash Equivalents and Short-Term Investments	263.00K	1.13M	2.03M	3.99M	2.39M	2.21M
Total Debt	15.39M	14.52M	13.47M	11.91M	11.69M	11.04M
Total Liabilities	16.93M	15.72M	14.52M	13.28M	12.82M	12.45M
Stockholders Equity	-8.58M	-6.52M	-3.07M	-843.00K	-2.77M	-3.36M
Cash Flow
Free Cash Flow	-1.48M	-1.05M	-718.00K	2.14B	8.80B	-9.07B
Operating Cash Flow	-1.21M	-826.00K	-481.00K	3.88B	10.52B	-7.74B
Investing Cash Flow	-273.00K	-224.00K	-424.00K	-21.67B	4.27B	-18.38B
Financing Cash Flow	368.00K	151.00K	-1.06M	-209.00K	-400.00K	-146.00K

Proteome Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Negative. The current price of 2.85 is below the 20-day moving average (MA) of 2.93, above the 50-day MA of 2.46, and above the 200-day MA of 2.72, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 36.40 is Neutral, neither overbought nor oversold. The STOCH value of 11.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRM.

Proteome Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRCI	58 Neutral	£10.97M	-0.30	-122.54%	―	-57.03%	-15.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLBX	48 Neutral	£13.64M	-0.25	-87.18%	―	29.64%	28.51%
GDR	47 Neutral	£11.07M	-1.16	-153.92%	―	90.42%	79.21%
OPTI	43 Neutral	£7.49M	-51.79	-2.42%	―	―	―
PRM	42 Neutral	£6.31M	-1.63	―	―	12.19%	18.12%
GENI	40 Underperform	£3.41M	-0.51	-181.41%	―	12.12%	54.24%

Proteome Sciences Corporate Events

Proteome Sciences Launches £60,000 UK Retail Offer to Fund Proteomics Expansion

Proteome Sciences has launched a UK-only retail share offer of up to 3,428,571 new ordinary shares at 1.75 pence per share, aiming to raise up to £60,000 from existing retail shareholders via the BookBuild platform, in parallel with a separate placing and subscription already completed at the same issue price. The proceeds from this combined equity raise will be directed towards expanding and upgrading the company’s proteomics technology suite—boosting TMT plexing from 32X to 96X, launching a new DXT isotopic tag range, introducing ‘Solvent Shift’ chemoproteomic workflows, concluding a DXT licence, and increasing staff and mass spectrometry capacity in San Diego—moves that are intended to support growing demand, enhance its technical offering and strengthen its competitive position in high-throughput proteomics, while also reinforcing engagement with its retail investor base.

The most recent analyst rating on (GB:PRM) stock is a Buy with a £3.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.

Proteome Sciences Raises £840,000 to Accelerate Proteomics Expansion and Tightens Loan Conversion Terms

Proteome Sciences has raised £840,000 through a placing and subscription of 48 million new shares at 1.75p, representing about 14% of its enlarged share capital, and plans an additional retail offer of up to £60,000 at the same price via the BookBuild platform. The funds will be used to scale its proteomics capabilities, including increasing TMT plexing capacity to 96-plex, launching new DXT isotopic tags, introducing solvent shift chemoproteomic workflows, concluding a DXT licence, expanding staff and mass spectrometry capacity in San Diego, and providing working capital, following recent substantial GCLP contract wins and biopharma deals in Europe and the US. Major shareholder Vulpes Life Science Fund and Chief Commercial Officer Richard Dennis participated in the raise, constituting related party transactions deemed fair and reasonable by independent directors, while Executive Chairman Christopher Pearce has agreed to raise the conversion price on his £5 million loan facility from 1p to a minimum of 4p per share, reducing potential dilution risk as the new shares are admitted to trading in London.

The most recent analyst rating on (GB:PRM) stock is a Buy with a £3.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.

Proteome Sciences Wins Two More Major GCLP Contracts Worth Over $1.5m

Proteome Sciences has secured two additional substantial GCLP contracts worth over $1.5 million, following an earlier announcement in December 2025, with trial samples scheduled to be shipped in late Q1 and most of the work to be completed during 2026. Management highlighted sustained strong demand from major biopharma clients in both the US and Europe, indicating that these new wins, combined with previously announced contracts, provide a robust order book that underpins the company’s revenue visibility and operational outlook through 2026.

The most recent analyst rating on (GB:PRM) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.

Proteome Sciences Secures Major Biopharma Contract

Proteome Sciences has secured a significant contract with a US biopharmaceutical company to develop a new assay using its mass spectrometry services in Frankfurt, Germany. This contract, which adheres to Good Clinical Laboratory Practice standards, is expected to enhance the company’s positioning in the industry by increasing demand for its services, with potential for further contracts in the coming years.

The most recent analyst rating on (GB:PRM) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.

Proteome Sciences Appoints New Nominated Adviser and Broker

Proteome Sciences has announced the appointment of SP Angel Corporate Finance LLP as its new Nominated Adviser and sole Broker, effective immediately. This strategic move is expected to enhance the company’s development efforts and strengthen its market position, potentially benefiting stakeholders by providing improved financial guidance and support.

The most recent analyst rating on (GB:PRM) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.